Cadila Pharmaceuticals has just announced the entry of its new drug for lung cancer management. This is seen as an important development in the treatment of lung cancer.
The drug, Mycidac-C, can be used for victims suffering from a cancer sub-type - non-small cell lung cancer.
Advertisement
10 injections come at a price of Rs.4000 and the total expenditure for therapy to patients is estimated at Rs 40,000.
Cadila CMD Dr Rajiv Modi said, "Our drug is a significant breakthrough in the management of squamous non-small cell lung cancer (NSCLC), since the introduction of first line cancer drugs nearly 30 years ago."
![Lung Cancer Screening]( "Lung Cancer Screening")
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.
According to Dr Modi, this drug can be used along with other cancer medication and trials on this drug has proved that it can boost median survival by over 40% in patients suffering from squamous NSCLC.
"It has taken us over a decade, a huge investment and a dedicated research and development team to develop this unique drug. We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years," Modi said.
Source: Medindia
Lung Cancer Screening
Lung cancer accounts for nearly 1.3 million deaths annually worldwide. Lung cancer screening can help in early detection of cancer and possible cure.
Advertisement
According to Dr Modi, this drug can be used along with other cancer medication and trials on this drug has proved that it can boost median survival by over 40% in patients suffering from squamous NSCLC.
"It has taken us over a decade, a huge investment and a dedicated research and development team to develop this unique drug. We expect it to be available in the Indian market by December 2013. Thereafter, we will introduce it in other regions like SAARC countries and European markets over the next five years," Modi said.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
A ray of hope for glioma patients as targeted therapy boosts treatment duration.
In patients with breast cancer combination therapy had increased invasive disease-free survival compared to those who were treated with the hormone therapy alone.
An antibody treatment helped shrink tumors in some patients with bile duct cancers.
Comprehending the association between the gut microbiome and polyp growth sheds insights into potential screenings and treatments.